Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
ABSTRACTBackground: Clinical outcome of patients with chronic myeloid leukemia (CML) has improved dramatically since the introduction of tyrosine kinase inhibitors such as imatinib mesylate (IM). However, approximately 20-30% of patients experience IM resistance. SH-4-54, which targets the SH2 domai...
Main Authors: | Lingling Yin, Jiawen Xu, Wenjian Wu, Mingshan Niu, Zhenyu Li, Feng Zhu, Kailin Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2224625 |
Similar Items
-
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
by: Bernhard Moser, et al.
Published: (2021-08-01) -
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells
by: Wioleta Dudka, et al.
Published: (2022-12-01) -
Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling
by: Qiong Su, et al.
Published: (2023-12-01) -
Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines
by: Mohammadi Kian M, et al.
Published: (2020-01-01) -
JAK/STAT in leukemia: a clinical update
by: Dong Liang, et al.
Published: (2024-01-01)